BB Biotech’s AveXis, Inc. Common Stock AVXS Stock Holding History

BB Biotech’s Portfolio AVXS Stock Details AVXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-402,800	Closed	-$49.8M	–	34
2018 Q1	$49.8M	Hold	402,800	–	–	1.38%	19
2017 Q4	$44.6M	Hold	402,800	–	–	1.26%	18
2017 Q3	$39M	Hold	402,800	–	–	1.08%	19
2017 Q2	$33.1M	Buy	402,800 +70,000	+21%	+$5.25M	1.01%	20
2017 Q1	$25.3M	Sell	332,800 -20,000	-6%	-$1.24M	0.83%	24
2016 Q4	$16.8M	Hold	352,800	–	–	0.62%	23
2016 Q3	$14.5M	Buy	+352,800	New	+$13.4M	0.51%	27

Other funds holding AVXS

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

BB Biotech's AVXS Position: Q2 2018 in Review

BB Biotech sold out of AveXis, Inc. Common Stock (AVXS) in Q2 2018, closing a stake of 402,800 shares — an estimated $49.8M sold.

BB Biotech first reported a position in AVXS in Q3 2016 and held it in 7 quarters. The position peaked at $49.8M in Q1 2018. 1 fund tracked by Wall St. Rank holds AVXS as of Q2 2018.

BB Biotech reported no remaining AveXis, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
BB Biotech sold 402,800 AveXis, Inc. Common Stock shares in Q2 2018, an estimated $49.8M.
BB Biotech first reported a position in AveXis, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
BB Biotech's AveXis, Inc. Common Stock position peaked at $49.8M in Q1 2018.
1 fund tracked by Wall St. Rank held AveXis, Inc. Common Stock as of Q2 2018.

Based on BB Biotech's 13F filing for Q2 2018, filed 9 Aug 2018.